Geulah Livshits
Stock Analyst at Chardan Capital
(2.09)
# 2,749
Out of 4,712 analysts
171
Total ratings
29.88%
Success rate
-1.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $212 | $160.49 | +32.10% | 8 | Dec 18, 2024 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $18 | $1.61 | +1,018.01% | 9 | Dec 18, 2024 | |
| EDIT Editas Medicine | Downgrades: Neutral | n/a | $1.23 | - | 10 | Dec 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $94 | $41.07 | +128.88% | 11 | Dec 10, 2024 | |
| SNTI Senti Biosciences | Maintains: Buy | $10 → $12 | $4.14 | +189.86% | 7 | Dec 4, 2024 | |
| IMRX Immuneering | Maintains: Buy | $13 | $2.18 | +496.33% | 8 | Nov 20, 2024 | |
| MGX Metagenomi | Maintains: Buy | $15 | $4.03 | +272.21% | 5 | Nov 20, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $62 | $12.02 | +415.81% | 14 | Nov 18, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $88 → $91 | $12.12 | +650.83% | 12 | Nov 18, 2024 | |
| PASG Passage Bio | Maintains: Buy | $7 | $0.66 | +960.77% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 | $1.86 | +276.34% | 11 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 | $5.81 | +571.26% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $15 | $2.94 | +410.20% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $6.78 | +268.73% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 | $14.89 | +88.05% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $4.37 | +243.25% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $11 | $1.08 | +918.52% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $1.15 | +421.74% | 5 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $7.60 | +347.37% | 10 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $6.11 | +571.03% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $7.06 | +254.11% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.49 | +381.93% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $40.43 | +414.47% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.77 | +803.95% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2.5 | $6.80 | -63.24% | 5 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $7.87 | +1,043.58% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $5.91 | -32.32% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $30 | $0.18 | +16,213.21% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $5.02 | +497.61% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $11.10 | +62.16% | 1 | Oct 27, 2020 |
Krystal Biotech
Dec 18, 2024
Maintains: Buy
Price Target: $212
Current: $160.49
Upside: +32.10%
Tenaya Therapeutics
Dec 18, 2024
Maintains: Buy
Price Target: $18
Current: $1.61
Upside: +1,018.01%
Editas Medicine
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.23
Upside: -
CRISPR Therapeutics AG
Dec 10, 2024
Maintains: Buy
Price Target: $94
Current: $41.07
Upside: +128.88%
Senti Biosciences
Dec 4, 2024
Maintains: Buy
Price Target: $10 → $12
Current: $4.14
Upside: +189.86%
Immuneering
Nov 20, 2024
Maintains: Buy
Price Target: $13
Current: $2.18
Upside: +496.33%
Metagenomi
Nov 20, 2024
Maintains: Buy
Price Target: $15
Current: $4.03
Upside: +272.21%
Rocket Pharmaceuticals
Nov 18, 2024
Maintains: Buy
Price Target: $62
Current: $12.02
Upside: +415.81%
Intellia Therapeutics
Nov 18, 2024
Maintains: Buy
Price Target: $88 → $91
Current: $12.12
Upside: +650.83%
Passage Bio
Nov 14, 2024
Maintains: Buy
Price Target: $7
Current: $0.66
Upside: +960.77%
Nov 14, 2024
Maintains: Buy
Price Target: $7
Current: $1.86
Upside: +276.34%
Nov 14, 2024
Maintains: Buy
Price Target: $39
Current: $5.81
Upside: +571.26%
Nov 13, 2024
Maintains: Buy
Price Target: $17 → $15
Current: $2.94
Upside: +410.20%
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $25
Current: $6.78
Upside: +268.73%
Nov 13, 2024
Maintains: Buy
Price Target: $28
Current: $14.89
Upside: +88.05%
Nov 11, 2024
Maintains: Buy
Price Target: $15
Current: $4.37
Upside: +243.25%
Nov 7, 2024
Maintains: Buy
Price Target: $17 → $11
Current: $1.08
Upside: +918.52%
Apr 5, 2024
Maintains: Buy
Price Target: $11 → $6
Current: $1.15
Upside: +421.74%
Feb 20, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $7.60
Upside: +347.37%
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $6.11
Upside: +571.03%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $7.06
Upside: +254.11%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $2.49
Upside: +381.93%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $40.43
Upside: +414.47%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.77
Upside: +803.95%
Aug 22, 2022
Maintains: Buy
Price Target: $4 → $2.5
Current: $6.80
Upside: -63.24%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $7.87
Upside: +1,043.58%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $5.91
Upside: -32.32%
Aug 13, 2021
Maintains: Buy
Price Target: $33 → $30
Current: $0.18
Upside: +16,213.21%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $5.02
Upside: +497.61%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $11.10
Upside: +62.16%